Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

38.78 -1.51 (-3.75%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 21, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,917,787
Open	40.47
Bid (Size)	38.00 (400)
Ask (Size)	39.90 (5,000)
Prev. Close	40.29
Today's Range	38.47 - 40.47
52wk Range	13.88 - 43.31
Shares Outstanding	60,717,176
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started? ↗

April 20, 2026

Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price gains.

Via The Motley Fool

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 14, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Performance

YTD	-1.9%	-1.9%
1 Month	+39.7%	+39.7%
3 Month	+38.8%	+38.8%
6 Month	+39.0%	+39.0%
1 Year	+156.7%	+156.7%

More News

These stocks are moving in today's session ↗

April 14, 2026

Via Chartmill

Travere Therapeutics (NASDAQ:TVTX) Posts Q4 Earnings Beat on Profitability Despite Revenue Miss ↗

February 19, 2026

Via Chartmill

Tuesday's session: gap up and gap down stocks ↗

April 14, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's pre-market session. ↗

April 14, 2026

Via Chartmill

Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases

March 31, 2026

Via MarketMinute

Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy

March 10, 2026

Via MarketMinute

Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

February 19, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗

February 17, 2026

Via The Motley Fool

Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗

February 17, 2026

Via The Motley Fool

Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗

February 17, 2026

Via The Motley Fool

Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗

February 17, 2026

Via The Motley Fool

Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 11, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit

February 04, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 25, 2026

Via The Motley Fool

Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗

January 24, 2026

Via The Motley Fool

TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

January 16, 2026

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Why Travere Therapeutics Stock Got Trounced on Tuesday ↗

January 13, 2026

Via The Motley Fool

Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS

January 13, 2026

Via MarketMinute

Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April ↗

January 13, 2026

Via Stocktwits

Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS

January 13, 2026

From Travere Therapeutics, Inc.

Via Business Wire

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

January 13, 2026

Via Chartmill

These stocks are gapping in today's session ↗

January 13, 2026

Via Chartmill

Frequently Asked Questions

Is Travere Therapeutics, Inc. - Common Stock publicly traded?

Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Travere Therapeutics, Inc. - Common Stock trade on?

Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?

The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market

What is the current price of Travere Therapeutics, Inc. - Common Stock?

The current price of Travere Therapeutics, Inc. - Common Stock is 38.78

When was Travere Therapeutics, Inc. - Common Stock last traded?

The last trade of Travere Therapeutics, Inc. - Common Stock was at 04/21/26 04:00 PM ET

What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?

The market capitalization of Travere Therapeutics, Inc. - Common Stock is 2.35B

How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?

Travere Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.